共 50 条
- [21] Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy[J]. BLOOD, 2022, 140 : 3139 - 3141Qi, JialeiEndres, SaschaYosifov, Deyan YordanovTausch, EugenDheenadayalan, Rashmi PriyadharshiniGao, XiangScheffold, AnnikaSeyfried, FelixMeyer, LuderSchneider, ChristofMertens, DanielGierschik, PeterWist, MartinStilgenbauer, StephanJebaraj, Billy Michael Chelliah
- [22] Discovery and preliminary characterization of novel tyrosine kinase inhibitors with to BTK[J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)Namdev, Nivedita D.Cornell-Kennon, SusanYu, YiHill, JasonBull, CathyVolak, LaurieWang, JianqiangLowe, DeirdreGu, XuibinKoerner, SteffiMoussa, MagdiVensel, DavidLiu, YanbinWu, HuiChen, Chang-RungDransfield, Daniel T.Ashwell, Mark A.
- [23] Discovery and development of novel covalent inhibitors of the YAP-TEAD transcription activity[J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Guo, ShirleyHuang, CindyBegley, C. GlennBishop, Michael J.Cao, Ping
- [24] Ibrutinib and novel BTK inhibitors in clinical development[J]. Journal of Hematology & Oncology, 6Akintunde AkinleyeYamei ChenNikhil MukhiYongping SongDelong Liu
- [25] Impact of genetic insights on the development of BTK inhibitors[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251Johnson, AdamBelmont, LisaBurton, LucianaChoy, ReginaCrawford, JamesEverett, ChristineKatewa, ArnaKohli, PawanOrtwine, DanielPenuel, EliciaYoung, Wendy
- [26] Understanding Resistance Mechanisms and Growth Kinetics of CLL Treated with Covalent and Non-Covalent BTK Inhibitors[J]. BLOOD, 2023, 142Naeem, AishathLi, LiangUtro, FilippoCha, JustinTsuji, JunkoFernandes, Stacey M.Azevedo, Roberta SantosMorelli, FrancescaWang, ZunqiuShupe, Samantha J.Rhrissorrakrai, KahnLevovitz, ChayaDanysh, Brian P.Kluge, AlexandriaDavids, Matthew S.Leshchiner, IgnatyParida, LaxmiGetz, GadBrown, Jennifer R.
- [27] Ibrutinib and novel BTK inhibitors in clinical development[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6Akinleye, AkintundeChen, YameiMukhi, NikhilSong, YongpingLiu, Delong
- [28] CFON-026 is a potent non-covalent BTK inhibitor suitable for combination therapy with covalent BTK inhibitors for early eradication of resistance mutations[J]. CANCER RESEARCH, 2024, 84 (06)de Man, JosMuller, MichelleUitdehaag, Joost C. M.van Cauter, Freekvan Gemert, SanderHoffmann, Milanvan Mil, Yvonne G. T. H.Mulder, Winfried R.Prinsen, Martine B. W.Sterrenburg, Jan GerardVu, Diepde Wit, JoeriEnsing, ErikBuijsman, Rogier C.
- [29] Discovery and improvement of covalent influenza neuraminidase inhibitors[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250Vavricka, ChrisMuto, ChiakiIzumi, MinoruKiyota, Hiromasa
- [30] Discovery of Potent and Selective Covalent Inhibitors of JNK[J]. CHEMISTRY & BIOLOGY, 2012, 19 (01): : 140 - 154Zhang, TinghuInesta-Vaquera, FranciscoNiepel, MarioZhang, JianmingFicarro, Scott B.Machleidt, ThomasXie, TingMarto, Jarrod A.Kim, NamDooSim, TaeboLaughlin, John D.Park, HajeungLoGrasso, Philip V.Patricelli, MattNomanbhoy, Tyzoon K.Sorger, Peter K.Alessi, Dario R.Gray, Nathanael S.